Constellation Pharmaceuticals, Inc., a Cambridge, Massachusetts-based biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, has raised $22m in a Series B financing round.
The round was led by SR One, the independent corporate healthcare venture capital arm of GlaxoSmithKline, with participation from existing investors Third Rock Ventures, The Column Group, Venrock, and Altitude Life Science Ventures.
This financing brings the total amount of capital raised by the company in the two years since its founding to $54m.
The capital infusion will be used to advance the development of Constellation’s pipeline of compounds towards the clinic. These funds will also allow the company to continue applying its innovative epigenetics product engine to probe multiple classes of novel drug targets involved in chromatin regulation and disease.